Polish scientists developed DK-AT390HCl from tryptamine derivatives with triazine and pyrimidine. Compound kills colorectal cancer cells effectively. Spares healthy cells almost completely. Inhibits autophagy allowing cancer cells to die during chemotherapy. Initially tested on breast cancer cells. Shows high therapeutic potential for colorectal cancer. Patented four times with two applications pending. Early in vivo safety profile promising. Team plans human tissue tests next. Considering sale to pharma company for clinical trials. Leader Damian Kułaga calls it early therapeutic system. Izabela Siemińska notes strong selectivity. Aims to block cancer cell survival mechanisms. Results highly promising for colorectal cancer treatment.